Meanwhile, the activation of Th1 cell responses increases the release of inflammatory mediators like IL-1 and TNF-α, exacerbating the skin’s inflammatory process.[37] The interplay between these immune cells and the regulation of the cytokine network are key elements in the pathophysiology of AD.[29,38] Current treatment approaches for AD include oral antihistamines, immunosuppressants, and topical corticosteroids.[11,39,40] In recent years, biologic agents and small molecule targeted drugs have also become frontline therapies for AD.[9,41]. The gene discussed is TNF; the disease is Alzheimer disease.